COVID-19 non-medical therapy

Jump to navigation Jump to search

For COVID-19 frequently asked inpatient questions, click here
For COVID-19 frequently asked outpatient questions, click here

COVID-19 Microchapters

Home

Long COVID

Frequently Asked Outpatient Questions

Frequently Asked Inpatient Questions

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating COVID-19 from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT scan

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Vaccines

Secondary Prevention

Future or Investigational Therapies

Ongoing Clinical Trials

Case Studies

Case #1

COVID-19 non-medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of COVID-19 non-medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on COVID-19 non-medical therapy

CDC on COVID-19 non-medical therapy

COVID-19 non-medical therapy in the news

Blogs on COVID-19 non-medical therapy

Directions to Hospitals Treating Psoriasis

Risk calculators and risk factors for COVID-19 non-medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Robert G. Badgett, M.D.[2],

Overview

COVID-19 is an inflammatory hypercytokinemia disease. The aim of therapy is prevention of viral replication and controlling the inflammatory process. On February 09, 2021 FDA approved emergency use authorization of monoclonal antibodies including bamlanivimab and etesevimab for mild to moderate covid-19 patients who are high risk for progression of disease ( age > 65years, medical comorbidities).

Current Non-Medical treatment

These treatments focus on long COVID syndrome:

References

  1. Liu Z, Qiao D, Xu Y, Zhao W, Yang Y, Wen D; et al. (2021). "The Efficacy of Computerized Cognitive Behavioral Therapy for Depressive and Anxiety Symptoms in Patients With COVID-19: Randomized Controlled Trial". J Med Internet Res. 23 (5): e26883. doi:10.2196/26883. PMC 8128049 Check |pmc= value (help). PMID 33900931 Check |pmid= value (help).
  2. Li J, Li X, Jiang J, Xu X, Wu J, Xu Y; et al. (2020). "The Effect of Cognitive Behavioral Therapy on Depression, Anxiety, and Stress in Patients With COVID-19: A Randomized Controlled Trial". Front Psychiatry. 11: 580827. doi:10.3389/fpsyt.2020.580827. PMC 7661854 Check |pmc= value (help). PMID 33192723 Check |pmid= value (help).